An un-commissioned randomized, placebo-controlled double-blind study to test the effect of deep sea fish oil as a pain reliever for dogs suffering from canine OA

BMC Veterinary Research

Outi Laitinen-Vapaavuori²  Jouni Junnila³  Anu Lappalainen²  Kari Elo¹  Johanna Roine¹  Anna Hielm-Björkman² 

[1] Faculty of Agriculture and Forestry. Department of Animal sciences, University of Helsinki, P.O.Box 28, Helsinki, FI-00014, Finland;Faculty of Veterinary Medicine, Department of Equine and Small Animal Medicine, University of Helsinki, P.O.Box 57, Helsinki, FI-00014, Finland;4Pharma Ltd., Metsänneidonkuja 6, Espoo, FI-02130, Finland

关键词: Double-blind;    RCT;    Joint;    Supplement;    Canine / Dog;    Fatty acid;    Omega-3;    Fish oil;    Pain;    Osteoarthritis;   

Others  :  1119730
DOI  :  10.1186/1746-6148-8-157

 received in 2012-04-05, accepted in 2012-07-23,  发布年份 2012

【 摘 要 】

Background

An un-commissioned randomized, double-blinded, placebo controlled clinical study was planned using a deep sea fish oil product for pets. Seventy-seven client-owned dogs with osteoarthritis were randomly assigned to supplement the food with either the fish oil product or corn (=placebo) oil. Our main outcome variables were force platform variables peak vertical force (PVF) and impulse, the validated Helsinki Chronic Pain Index (HCPI) and the use of rescue NSAIDs. Secondary outcome variables were a locomotion visual analog scale (VAS), a Quality of life VAS, a comparative questionnaire, a veterinary assessment, owners’ final assessment of outcome and guessing the product given.

Results

When comparing the two test groups at the end of the trial (16 weeks) there was no significant difference in any of the main outcome variables but owners of dogs that had taken fish oil were significantly happier with the treatment at the end visit and did significantly better at guessing what group their dogs had been in, compared to the placebo group. When comparing variables within the fish oil group as change from baseline to trial end, there were significant positive changes in PVF, HCPI, NSAID use, Quality of life VAS, as well as in all three scores in the comparative questionnaire (locomotion, every-day situations, and skin & coat). There were similar positive trends in force platform impulse and in the veterinary assessment variables, although they did not reach significance. Within the placebo group there were significant positive changes only in the HCPI and a significant deterioration according to veterinary assessment.

Conclusions

When compared to placebo, there was not a major statistically significant benefit in using deep sea fish oil as a pain reliever in our study population of dogs suffering from osteoarthritis. However, the fish oil treated patients improved significantly in many of the variables, when comparing baseline values to the study-end values within the group, indicating a true but small relief in symptoms. Deep sea fish oil supplementation could be considered a part of the multimodal pain relieving approach currently recommended for dogs suffering from OA, especially for individuals that do not tolerate anti-inflammatory drugs.

【 授权许可】

   
2012 Hielm-Björkman et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Johnston SA: Osteoarthritis. Joint anatomy, physiology, and pathobiology. Vet Clin North Am Small Anim Pract 1997, 27:699-723.
• [2]Canine osteoarthritis - initiating factors. Genova; 2005:6-13. [Hill’s European symposium on osteoarthritis and joint health]
• [3]Pelletier JP, Martel-Pelletier J, Raynauld JP: Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow. Arthritis Res Ther 2006, 8:206. BioMed Central Full Text
• [4]Schulz K: Diseases of the joints. In Small Animal Surgery. 3rd edition. Edited by Fossum TW. Mosby Elsevier, Saint Louis, Missouri; 2007:1145-1150.
• [5]Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JWJ, Cluzeau F, Cooper C, Dieppe PA, Gunther KP, Hauselmann HJ, Herrero-Beaumont G, Kaklamanis PM: EULAR recommendations for the management of knee osteoarthritis. Report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis 2000, 59:936-944.
• [6]Kremer JM, Jubiz W, Michalek A, Rynes RI, Bartholomew LE, Bigaouette J, Timchalk M, Beeler D, Lininger L: Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Ann Intern Med 1987, 106:497-503.
• [7]Nielsen GL, Faarvang KL, Thomsen BS, Teglbjaerg KL, Jensen LT, Hansen TM, Lervang HH, Schmidt EB, Dyerberg J, Ernst E: The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with Rheumatoid arthritis: a randomized, double blind trial. Eur J Clin Invest 1992, 22:687-691.
• [8]Berbert AA, Kondo CR, Almendra CL, Matsuo T, Dichi I: Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. Nutrition 2005, 21:131-136.
• [9]Goldberg RJ, Katz J: A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory join pain. Pain 2007, 129:210-223.
• [10]Galarraga B, Ho M, Youssef HM, Hill A, Hall C, Nuki G, Belch JJF: Cod liver oil (n-3 fatty acids) as a non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology 2008, 47:665-669.
• [11]Miller WH Jr: Fatty acid supplements as anti-inflammatory agents. In Current veterinary therapy X. Edited by Kirk RW. W.B.Saunders, Philadelphia, USA; 1989:565.
• [12]Scott DW, Miller WH Jr: Nonsteroidal anti-inflammatory agents in the management of canine pruritus. J S Afr Vet Assoc 1993, 64:52-56.
• [13]Roush JK, Dodd CE, Fritsch DA, Allen TA, Jewell DE, Schoenherr WD, Richardson DC, Leventhal PS, Hahn KA: Multicenter veterinary practice assessment of the effects of omega-3 fatty acids on osteoarthritis in dogs. J Am Vet Med Assoc 2010, 236:59-66.
• [14]Roush JK, Cross AR, Renberg WC, Dodd CE, Sixby KA, Fritsch DA, Allen TA, Jewell DE, Richardson DC, Leventhal PS, Hahn KA: Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs with ostoearthritis. J Am Vet Med Assoc 2010, 236:67-73.
• [15]Fritsch DA, Allen TA, Dodd CE, Jewell DE, Sixby KA, Leventhal PS, Brejda J, Hahn KA: A multicenter study of the effect of dietary supplementation with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis. J Am Vet Med Assoc 2010, 235:535-539.
• [16]Fritsch D, Allen TA, Dodd CE, Jewell DE, Sixby KA, Leventhal PS, Hahn KA: Dose-Titration Effects of Fish Oil in Osteoarthritic Dogs. J Vet Intern Med. 2010, 24:1020-1026.
• [17]Calder PC: n-3 polyunsaturated fatty acids, inflammation and inflammatory diseases. Am J Clin Nutr 2006, 83:1505S-1519S.
• [18]Calder PC: Dietary modification of inflammation with lipids. Proc of the Nutrition Society 2002, 61:345-358.
• [19]Calder PC: n-3 fatty acids, inflammation, and immunity- relevance to postsurgical and critically ill patients. Lipids 2004, 39:1147-1161.
• [20]Manhart DR, Scott BD, Eller EM, Honnas CM, Hood DM, Coverdale JA, Gibbs PG: Effect of n-3 PUFAs on markers of inflammation in arthritic horses. Equine Sci. Soc, Savoy, IL; 2007:11-12. [Proc.20th Equine Sci. Soc., Hunt Valley, MD]
• [21]Thies F, Nebe-von-Caron G, Powell JR, Yaqoob P, Newsholme EA, Calder PC: Dietary supplementation with eicosapentaenoic acid, but not with other long chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55y. Am J Clin Nutr 2001, 73:539-548.
• [22]Hall JA, Henry LR, Jha S, Skinner MM, Jewell DE, Wander RC: Dietary (n-3) fatty acids alter plasma fatty acids and leukotrien B synthesis by stimulated neutrophils from healthy geriatric Beagles. Prostaglandins Leukot Essent Fatty Acids 2005, 73:335-341.
• [23]Hall JA, Picton RA, Skinner MM, Jewell DE, Wander RC: The (n-3) fatty acid dose, independent of the (n-6) to (n-3) fatty acid ratio, affect the plasma fatty acid profile of normal dogs. J Nutr 2006, 136:2338-2344.
• [24]Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, van der Meer JW, Cannon JG, Rogers TS, Klempner MS, Weber PC, Schaefer EJ, Wolff SM, Dinarello CA: The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Eng J Med 1989, 320:265-271.
• [25]Wachtler P, Konig W, Senkal M, Kemen M, Koller M: Influence of a total parenteral nutrition enriched with ω-3 fatty acids on leukotriene synthesis of peripheral leukocytes and systemic cytokine levels in patients with major surgery. J Trauma 1997, 42:191-198.
• [26]Venkatraman JT, Chu WC: Effects of dietary ω-3 and ω-6 lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. J Am Coll Nutr 1999, 18:602-613.
• [27]Bauer JE: Responses of dogs to dietary omega-3 fatty acids. J Am Vet Med Assoc 2007, 231:1657-1661.
• [28]Hansen RA, Harris MA, Pluhar GE, Motta T, Brevard S, Ogilvie GK, Fettman MJ, Allen KGD: Fish oil decreases matrix metalloproteinases in knee synovia of dogs with inflammatory joint disease. J Nutr Biochem 2008, 19:101-108.
• [29]Remillard RL: Omega 3 fatty acids in canine and feline diets: a clinical success or failure? Vet Clin Nutr 1998, 5:6-11.
• [30]Jacquet A, Girodet P-O, Pariente A, Forest K, Mallet L, Moore N: Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomized double-blind placebo-controlled clinical trial. Arthritis Res Ther 2009, 11:R192. BioMed Central Full Text
• [31]Christensen R, Bliddal H: Is Phytalgic a goldmine for osteoarthritis patients or is there something fishy about this nutraceutical? A summary of findings and risk-of-bias assessment. Arthritis Res Ther 2009, 12:105.
• [32]Caturla N, Funes L, Perez-Fons L, Micol V: A randomized double-blinded, placebo controlled study of the effect of a combination of lemon verbena extract and fish oil omega-3 fatty acid on joint management. J Altern Complement Med 2011, 17:1051-1063.
• [33]Gruenwald J, Petzold E, Busch R, Petzold H-P, Graubaum H-J: Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with OA. Adv Ther 2009, 26:858-871.
• [34]Filburn CR, Griffin D: Canine Plasma and erythrocyte response to a docosahexaenoic acid-enriched supplement: Characterization and potential benefits. Vet Therapeutics 2005, 6:29-42.
• [35]Wander R, Hall JA, Gradin JL, Du SH, Jewell DE: The ratio of dietary (n-6) to (n-3) fatty acids influences immune system function, eicosanoid metabolism, lipid peroxidation, and vitamin E status in aged dogs. J Nutr 1997, 127:1198-1205.
• [36]Zainal Z, Longman AJ, Hurst S, Duggan K, Caterson B, Hughes CE, Harwood JL: Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis. Osteoarthr Cartil 2009, 17:896-905.
• [37]Kremer JM, Bigauoette J, Michalek AV, Timchalk MA, Lininger L, Rynes RI, Huyck C, Zieminski J, Bartholomew LE: Effects of manipulation of dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1985, 8422:184-187.
• [38]Salomon P, Asher A, Kornbluth AA, Janowitz HD: Treatment of ulcerative colitis with fish oil n-3 fatty acid: an open trial. J Clin Gastroeterol 1990, 12:157-161.
• [39]Almallah YZ, El Tahir A, Heys SD, Richardson S, Eremin O: Distal proctocolitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition. Eur J Clin Invest 2000, 30:58-65.
• [40]Blonk MC, Bilo HJ, Nauta JJ, Popp-Snijders C, Mulder C, Donker AJ: Dose–response effects of fish-oil supplementation in healthy volunteers. Am J Clin Nutr 1990, 52:120-127.
• [41]Ackman RG, Ratnayake WMN, Macpherson EJ: EPA and DHA Contents of Encapsulated Fish Oil Products. J Am Oil Chem Soc 1989, 66:1162-1164.
• [42]Kremer JM: Clinical studies on Omega-3 fatty acid supplementation in patients who have rheumatoid arthritis. Rheum Dis Clin North Am 1991, 17:391-402.
• [43]Schulz KF, Altman DG, Moher D, for the CONSORT Group: CONSORT 2010 Statement: updating guidelines for reporting parallel group randomized trials. Br Med J 2010., 340
• [44]Hielm-Björkman A, Kuusela E, Liman A, Markkola A, Saarto E, Huttunen P, Leppäluoto J, Tulamo R-M, Raekallio M: A: Evaluation of methods for assessment of pain associated with chronic osteoarthritis in dogs. J Am Vet Med Assoc 2003, 222:1552-1558.
• [45]Hielm-Björkman A, Rita H, Tulamo R-M: Psychometric testing of the Helsinki chronic pain index by completion of a questionnaire in Finnish by owners of dogs with chronic signs of pain caused by osteoarthritis. Am J Vet Res 2009, 70:727-734.
• [46]Wernham BG, Trumpatori B, Hash J, Lipsett J, Davidson G, Wackerow P, Thomson A, Lascelles BD: Dose reduction of meloxicam in dogs with osteoarthritis-associated pain and impaired mobility. J Vet Intern Med 2011, 25:1298-1305.
• [47]Hielm-Björkman A: Helsinki Chronic Pain Index. Available at http://www.vetmed.helsinki.fi/english/animalpain/hcpi/index.html webcite
• [48]Eskelinen EV, Liska WD, Hyytiäinen HK, Hielm-Björkman A: Canine total knee replacement performed due to osteoarthritis subsequent to distal femur fracture osteosynthesis and a two-year objective outcome. Vet Comp Ortho Trauma 2012., 25(5) [epub ahead of print]
• [49]Budsberg SC: Long-term temporal evaluation of ground reaction forces during development of experimentally induced osteoarthritis in dogs. Am J Vet Res 2001, 62:1207-1211.
• [50]Hielm-Björkman A, Tulamo R-M, Salonen H, Raekallio M: Evaluating a complementary therapy for moderate to severe canine osteoarthritis. Part I: Green Lipped Mussel (Perna canaliculus). Evid Based Complement Alternat Med 2009, 6:365-373.